Stock-Based Compensation for Insulet (PODD)
Stock-Based Compensation for Insulet (PODD): headline value $42.40M · YoY -9.5%. Annual and quarterly series, chart, and tables are below.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
PODD
Currently viewingStock-Based CompensationSwitch metric
Latest period
$42.40M
YoY change
-9.5%
5Y CAGR
+11.8%
Peak year (2024)
$69.30M
Latest annual
$62.70M
Stock-Based Compensation history chart for Insulet (PODD) from 2004 to 2025
Stock-Based Compensation history table for Insulet (PODD) from 2004 to 2025
| Fiscal year | Period ended | Reported | Stock-Based Compensation | YoY |
|---|---|---|---|---|
| 2025 | $62.70M | -9.5% | ||
| 2024 | $69.30M | +43.5% | ||
| 2023 | $48.30M | +18.1% | ||
| 2022 | $40.90M | +18.9% | ||
| 2021 | $34.40M | -4.2% | ||
| 2020 | $35.90M | +25.1% | ||
| 2019 | $28.70M | -23.5% | ||
| 2018 | $37.50M | +17.6% | ||
| 2017 | $31.90M | +35.1% | ||
| 2016 | $23.62M | +23.1% | ||
| 2015 | $19.18M | -14.8% | ||
| 2014 | $22.52M | +77.6% | ||
| 2013 | $12.68M | +27.9% | ||
| 2012 | $9.92M | +28.3% | ||
| 2011 | $7.73M | +52.7% | ||
| 2010 | $5.06M | +20.5% | ||
| 2009 | $4.20M | +24.8% | ||
| 2008 | $3.37M | — | ||
| 2007 | $0 | — | ||
| 2006 | $0 | — | ||
| 2005 | $0 | — | ||
| 2004 | $0 | — |
Stock-Based Compensation values are taken from Insulet's reported cash flow statements (10-Q quarterly and 10-K annual filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the date the filing was reported; YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
Analysis
As of the 2025 fiscal year, Insulet (PODD) reported stock-based compensation of $62.70M – declined 9.5% year-over-year.
Looking at the 2020–2025 (5 years) stretch, Insulet stock-based compensation compounded at +11.8% per year, with the latest reading among the more recent periods of the dataset.
2024 marks the peak stock-based compensation at $69.30M, with the historical low of $0 recorded in 2004.
Insulet (PODD) sits 5th of 8 Healthcare peers we track on this metric, against a peer median of $313.00M.
Insulet Stock-Based Compensation by Year
Insulet Stock-Based Compensation 2025: $62.70M
Insulet stock-based compensation in 2025 was $62.70M, declined 9.5% below 2024.
Insulet Stock-Based Compensation 2024: $69.30M
Insulet stock-based compensation in 2024 was $69.30M, surged 43.5% from 2023. This figure represents the highest annual value in the available history.
Insulet Stock-Based Compensation 2023: $48.30M
Insulet stock-based compensation in 2023 was $48.30M, grew 18.1% from 2022.
Insulet Stock-Based Compensation 2022: $40.90M
Insulet stock-based compensation in 2022 was $40.90M, grew 18.9% from 2021.
Insulet Stock-Based Compensation 2021: $34.40M
Insulet stock-based compensation in 2021 was $34.40M.
See more financial history for Insulet (PODD).
Sector peers — Stock-Based Compensation
Companies in the same sector as Insulet, ranked by their latest stock-based compensation.
| Company | Stock-Based Compensation | Sector |
|---|---|---|
| Johnson & Johnson (JNJ) | $1.35B | Healthcare |
| UnitedHealth Group Incorporated (UNH) | $971.00M | Healthcare |
| AbbVie Inc. (ABBV) | $955.00M | Healthcare |
| Eli Lilly and Company (LLY) | $626.00M | Healthcare |
| AstraZeneca PLC (AZN) | $0 | Healthcare |
| Merck & Co., Inc. (MRK) | $0 | Healthcare |
| Amgen Inc. (AMGN) | $0 | Healthcare |
| Novo Nordisk A/S (NVO) | $0 | Healthcare |
Frequently asked questions
What is Insulet's stock-based compensation?
Latest reported stock-based compensation for Insulet (PODD) is $42.40M (period ending December 31, 2025).
How has Insulet stock-based compensation changed year-over-year?
Insulet (PODD) stock-based compensation changed -9.5% year-over-year on the latest annual filing.
What is the long-term growth rate of Insulet stock-based compensation?
Insulet (PODD) stock-based compensation compound annual growth rate is +11.8% over the most recent 5 years available.
When did Insulet stock-based compensation hit its highest annual value?
Insulet stock-based compensation reached its highest annual value of $69.30M in 2024.
What was Insulet stock-based compensation in 2024?
Insulet (PODD) stock-based compensation in 2024 was $69.30M.
What was Insulet stock-based compensation in 2025?
Insulet (PODD) stock-based compensation in 2025 was $62.70M.
Metrics overview
Pick a metric for charts, filings and peers — each row shows the latest TTM or most-recent-quarter value.
Explore more
PODD Overview
Company profile, financial tools, and key metrics
PODD Revenue Counter
Earns $85.88 every second. See per minute, hour, and day.
PODD Earnings Counter
Earns $7.84 per second net profit. See per minute, hour, and day.
PODD Economic Scale
Exceeds St. Lucia's GDP. Compare with world economies.
PODD What If Invested
What if you had invested $1,000? See historical returns from any date.
PODD How It Makes Money
Discover visual breakdown of $2.71B in revenue — where it comes from and where it goes.
PODD Stock Seasonality
Best and worst months to invest. Historical monthly returns heatmap.
PODD Price Target Scenarios
Model bear, base, and bull cases with EPS growth and exit P/E — pre-filled from analysts and history.
PODD Daily Price Character
Explosive · 51.5% historical win rate (green days). Streaks & record days.
PODD Buybacks
0.30% TTM buyback yield. Shareholder yield & SBC comparison.